Your browser doesn't support javascript.
loading
IMPROVER (Involving Men with Prostate Cancer in Engaged Research): Assessing Patient Experience With Testing, Diagnosis, And Surveillance.
Walsh, Marc; Jordan, Asia; Schäfer, Lea; Joha, Jana; Heapes, Ben; Noonan, Megan; Gallagher, William; Gallagher, Hubert; Manecksha, Rustom P; Galvin, David; Nason, Greg; Martin, Terri; Lyons, Ciara; O'Connor, Robert; Drummond, Frances J; Kilty, Claire; Perry, Antoinette S.
Affiliation
  • Walsh M; Cancer Biology and Therapeutics Laboratory, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland; School of Biology and Environmental Science, University College Dublin, Dublin, Ireland.
  • Jordan A; Cancer Biology and Therapeutics Laboratory, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland; School of Biology and Environmental Science, University College Dublin, Dublin, Ireland.
  • Schäfer L; Cancer Biology and Therapeutics Laboratory, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland; School of Biology and Environmental Science, University College Dublin, Dublin, Ireland.
  • Joha J; Cancer Biology and Therapeutics Laboratory, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland; School of Biology and Environmental Science, University College Dublin, Dublin, Ireland.
  • Heapes B; Cancer Biology and Therapeutics Laboratory, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland; School of Biology and Environmental Science, University College Dublin, Dublin, Ireland.
  • Noonan M; Breakthrough Cancer Research, Cork, Ireland.
  • Gallagher W; Cancer Biology and Therapeutics Laboratory, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland; School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland.
  • Gallagher H; Department of Urology, Beacon Hospital, Sandyford, Dublin, Ireland.
  • Manecksha RP; Department of Urology, Tallaght University Hospital, Dublin, Ireland; Department of Surgery, Trinity College Dublin, Dublin, Ireland.
  • Galvin D; Department of Urology, St. Vincent's University Hospital, Dublin, Ireland.
  • Nason G; Department of Urology, Mater Misericordiae University Hospital, Dublin, Ireland.
  • Martin T; Clinical Research Centre, University College Dublin, Dublin, Ireland.
  • Lyons C; Department of Radiology, Cork University Hospital, Cork, Ireland.
  • O'Connor R; Irish Cancer Society, Dublin, Ireland.
  • Drummond FJ; Breakthrough Cancer Research, Cork, Ireland.
  • Kilty C; Irish Cancer Society, Dublin, Ireland.
  • Perry AS; Cancer Biology and Therapeutics Laboratory, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland; School of Biology and Environmental Science, University College Dublin, Dublin, Ireland. Electronic address: antoinette.perry@ucd.ie.
Clin Genitourin Cancer ; 22(3): 102063, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38537420
ABSTRACT

BACKGROUND:

Our understanding of patient experiences with prostate cancer testing for diagnosis and surveillance is limited. The aim of this study was to collaborate with patients and clinicians to understand their lived experience and unmet needs around the early detection, diagnosis and monitoring (active surveillance) of prostate cancer.

METHODS:

Two focus groups were held with patients (n = 20) and healthcare professionals (n = 16), to identify the main challenges in prostate cancer detection, diagnosis, and monitoring. This information formed the basis of an online questionnaire for broader dissemination.

RESULTS:

A total of 1138 analyzable responses were obtained from people tested for prostate cancer (69% tested positive) in Europe and the US. Only 29 healthcare professionals completed the survey. Almost one-third of people reported knowing very little/nothing about prostate cancer prior to testing. Prior disease awareness was significantly higher in those who tested negative (P < .0001). Most respondents (n = 857; 75%) felt informed about the steps involved in testing. Receiving written information was a key factor; 91% of those who felt uninformed were not given any written information. Overall, most people felt "satisfied" with the typical prostate cancer tests PSA, DRE, mpMRI, and biopsy. However, dissatisfaction for prostate biopsy (12%) was almost double that of other tests (P < .0001). Most patients understood why each test was done, and felt that their results and next steps were clearly explained to them; though PSA scored lowest in all of these fields. Apart from PSA, test satisfaction was lower when used repeatedly for surveillance, compared to once-off detection/diagnosis.

CONCLUSIONS:

Greater public awareness and education around prostate cancer, as well as clear and accessible written information for patients at the beginning of their cancer journey is needed. Further research is needed into alternative, less invasive tests, particularly when used repeatedly in the surveillance population.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Focus Groups / Early Detection of Cancer Limits: Aged / Humans / Male / Middle aged Country/Region as subject: America do norte / Europa Language: En Journal: Clin Genitourin Cancer Journal subject: NEOPLASIAS / UROLOGIA Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Focus Groups / Early Detection of Cancer Limits: Aged / Humans / Male / Middle aged Country/Region as subject: America do norte / Europa Language: En Journal: Clin Genitourin Cancer Journal subject: NEOPLASIAS / UROLOGIA Year: 2024 Document type: Article Affiliation country:
...